BMS-582949 hydrochloride

• CAT Number: I005442
• CAS Number: 912806-16-7
• Molecular Formula: C22H27ClN6O2
• Molecular Weight: 442.94
• Purity: ≥95%
• Synonyms: BMS582949 hydrochloride
• Target: Autophagy
• Solubility: DMSO: ＞ 35 mg/mL
• Storage: Store at -20°C
• IC50: 13 nM
• IUPAC Name: 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide;hydrochloride
• InChI: InChI=1S/C22H26N6O2.ClH/c1-4-9-23-22(30)17-11-28-19(14(17)3)20(24-12-25-28)27-18-10-15(6-5-13(18)2)21(29)26-16-7-8-16;/h5-6,10-12,16H,4,7-9H2,1-3H3,(H,23,30)(H,26,29)(H,24,25,27);1H
• InChIKey: BIYQUPNVBIOJIY-UHFFFAOYSA-N
• SMILES: CCCNC(=O)C1=CN2C(=C1C)C(=NC=N2)NC3=C(C=CC(=C3)C(=O)NC4CC4)C.Cl

BMS-582949 hydrochloride（Cat No.:I005442）is a selective, orally active inhibitor of p38 MAPK (mitogen-activated protein kinase), specifically targeting the α isoform. p38 MAPK is involved in the regulation of inflammatory responses and cytokine production, making BMS-582949 hydrochloride useful for studying inflammation-related diseases such as rheumatoid arthritis and other autoimmune conditions. By inhibiting p38α, it effectively reduces the production of pro-inflammatory cytokines like TNF-α and IL-1β. BMS-582949 hydrochloride is a valuable research tool for exploring the therapeutic potential of p38 MAPK inhibition in inflammatory and immune-mediated disorders.

Reference

[1]. Liu C, et al. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem. 2010 Sep 23;53(18):6629-39. 


[2]. Emami H, et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis. 2015 Jun;240(2):490-6.